My first book-chapter: Staphylococcus aureus (organism of my Ph.D thesis as well)
Hariharan pursued his doctoral studies at Orchid Pharma and registered with Dr. Gnanamani at Microbiology Division, CSIR-CLRI, Chennai. He is an amazing scientist whom I have met in my career who is very sharp, diligent and passionate researcher. He took ownership of work (without time restrictions) and work hard to meet Orchid’s demands and his thesis demands. This publication is part our first exercise to write a book chapter, and we succeeded in this with Hariharan taking the lead.
This review work was conducted at Orchid Pharma in the Division of Anti-infective New Drug Discovery in collaboration with Microbiology Division, CSIR-CLRI, Chennai, between 2006 to 2013.
Arumugam Gnanamani, Periasamy Hariharan and Maneesh Paul-Satyaseela (March 8th 2017).
Frontiers in Staphylococcus aureus, Editors: Shymaa Enany and Laura E. Crotty Alexander, IntechOpen,
https://doi.org/10.5772/67338
Staphylococcus aureus: Overview of Bacteriology, Clinical Diseases, Epidemiology, Antibiotic Resistance and Therapeutic Approach
Staphylococcus aureus is an important human pathogen that causes wide range of infectious conditions both in nosocomial and community settings. The Gram-positive pathogen is armed with battery of virulence factors that facilitate to establish infections in the hosts. The organism is well known for its ability to acquire resistance to various antibiotic classes. The emergence and spread of methicillin-resistant S. aureus (MRSA) strains which are often multi-drug resistant in hospitals and subsequently in community resulted in significant mortality and morbidity. The epidemiology of MRSA has been evolving since its initial outbreak which necessitates a comprehensive medical approach to tackle this pathogen. Vancomycin has been the drug of choice for years but its utility was challenged by the emergence of resistance. In the last 10 years or so, newer anti-MRSA antibiotics were approved for clinical use. However, being notorious for developing antibiotic resistance, there is a continuous need for exploring novel anti-MRSA agents from various sources including plants and evaluation of non-antibiotic approaches.
Originally published at http://discover.ind.in on June 6, 2021.
